Advertisement
Advertisement
Eric Ng
News Editor, Climate
Eric joined the Post in 1998 after brief stints in a trading company, and translation and editing roles at Dow Jones and Edinburgh Financial Publishing. He has over 20 years of experience covering China's energy, mining and industrial materials sectors, and has reported on China's healthcare and biotechnology sectors for three years. Currently, he leads the Post's coverage on climate change, energy transition and sustainability topics. Eric has a Masters of Business Administration degree.
Eric joined the Post in 1998 after brief stints in a trading company, and translation and editing roles at Dow Jones and Edinburgh Financial Publishing. He has over 20 years of experience covering China's energy, mining and industrial materials sectors, and has reported on China's healthcare and biotechnology sectors for three years. Currently, he leads the Post's coverage on climate change, energy transition and sustainability topics. Eric has a Masters of Business Administration degree.
Areas of Expertise:
Energy, industrial materials, biotechnology Languages Spoken:
English, Mandarin, Cantonese
Company raised US$20 million of fresh capital last month from investors including existing backer Lilly Asia Ventures.
Chinese regulator grants second approval for lung cancer drug ivonescimab, which has outperformed Merck’s Keytruda in phase three trial.
Chinese firms have been exporting from offshore factories to beat US tariffs for a decade, and Washington is determined to shut the loophole.
State-backed energy firms and private distributors may have to renegotiate long-term liquefied-natural-gas contracts, analysts say.
Advertisement
Foresight in building offshore factories to benefit Qingdao Sentury, Sailun Group as exporters navigate higher US tariffs on auto parts.
Xpeng’s Turing AI chip is three times more powerful in computing power than the Nvidia chip installed in its existing EVs.
Blood-cancer medicine, manufactured in the US, won conditional approval for sale in mainland China last month.
With biotech firms caught in the crosshairs of Trump’s tariffs, the levy could prove to be a boon for domestic producers but a bane for exporters.
Treatment uses electric pulses to kill prostate cancer cells while minimising risks of incontinence and sexual dysfunction.
Hong Kong biotech start-up works with university partners to conduct global clinical trials studying prevalent eye diseases.
Chinese company says DeepSeek’s AI model will enhance data mining in its platform, delivering efficiency to hospitals and pharmacies.
Natixis says China’s power-equipment industry needs to shift its investment focus to storage and distribution infrastructure.
A pilot programme in Shenzhen showed that trucks that run on batteries beat diesel-fuelled vehicles in terms of total cost of ownership.
ATRenew, China’s largest platform for pre-owned electronics, is offering trade-in incentives to coincide with the Lunar New Year holiday.
China has 4,804 new drug candidates under development, second only to the US at 5,268, according to data provider PharmCube.
London-based fund manager Climate Asset Management touts long-term investment benefits, as such investments are about to take off.
Reliance on dirty energy sources remained big at 48 per cent of projects in 2024, versus 55 per cent in 2022, report showed.
City must take care setting usage targets and provide airlines with assurance of carbon-reduction benefits, forum speakers say.
A decline in profit at the firm’s Chilean unit, forex losses and asset impairments contributed to the poor results in 2024.
The deal will combine Towngas’ strengths in green methanol production with Global Energy’s supply chain management.
Fidelity International report shows growth in attendance at general meetings of mainland-listed companies has slowed.
Prices of most popular solar modules have fallen to a level that renders most producers unprofitable, Citigroup says.
Hans Group, Citybus and Grand Resource Hydrogen signed a supply agreement on Wednesday.
Palbociclib, developed by Pfizer for certain types of advanced breast cancer, was approved for sale in 2015.
Developer urges quicker regulatory progress and pilot programmes to expedite low-carbon material adoption, vital for decarbonising the sector.
Oculis’ OCS-01 eye drops, currently in phase 3 trials for diabetic macular edema, can be an alternative to injection, CEO says.
Hong Kong has to act fast if it wants to become a green fuel hub for the aviation and maritime sectors, as both Singapore and China are way ahead, analysts say.
Companies face nearly US$770 million in spending they cannot handle without business model changes, says government-commissioned report.
Plasticvore is a two-year old biotech start-up offering alternative, humane solutions to controlling and eliminating pests, founder says.
